
-
Pieris Pharmaceuticals NASDAQ:PIRS Pieris Pharmaceuticals Inc.is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Its pipeline includes inhalable Anticalin proteins to treat respiratory diseases and immuno-oncology multi-specifics tailored for the tumor microenvironment. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris.
Location: 255 State St Fl 9, Massachusetts, 02109-2615, US | Website: www.pieris.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.327M
Cash
19.73M
Avg Qtr Burn
-9.467M
Short % of Float
2.78%
Insider Ownership
0.07%
Institutional Own.
52.92%
Qtr Updated
06/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Elarekibep (PRS-060/AZD1402) Details Asthma, Lung disease | Failed Discontinued | |
PRS-344/S095012 Details Solid tumor/s, Cancer | Failed Discontinued | |
Cinrebafusp Alfa (PRS-343) (4-1BB/HER2 Bispecific) Details Solid tumor/s, Cancer | Failed Discontinued | |
PRS-220 (CTGF) Details Idiopathic pulmonary fibrosis | Failed Discontinued |